跳至主要内容
临床试验/NCT06084858
NCT06084858已完成不适用

Effect of Dialysate Bicarbonate Prescription on Serum Calcification Propensity and Calciprotein Particles in Hemodialysis Patients

Prim. Priv. Doz. Dr. Daniel Cejka2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2023年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
26
试验地点
2
主要终点
T50-Laboratory Test for measuring calcification

研究概览

简要总结

This is a single-center, prospective, proof-of-priciple, pilot study in 24 end-stage renal disease patients on chronic hemodiaysis.

详细描述

This single-arm, proof-of-principle study will be conducted at the dialysis facility of the Ordensklinikum Linz Elisabethinen Hospital. The dialysate bicarbonate prescription will be decreased from standard of care (usually 35mmol/l) in a stepwise fashion (2 mmol/l per change) to 27 mmol/l and subsequentially increased in a stepwise fashion (2 mmol/l per change) to 37 mmol/l over the course of 6 weeks.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Sequential
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age ≥18 years
  • chronic (≥3 months) treatment with hemodialysis or hemodiafiltration
  • stable clinical condition

排除标准

  • inability to provide informed consent
  • dialysis treatment less than thrice weekly
  • morbid obesity (body mass index >40 kg/m2)
  • chronic inflammation (C reactive protein >10 mg/dL, reference: <0.5 g/dL)
  • current immunosuppressive medication,
  • severe chronic obstructive pulmonary disease (COPD stage III or IV)
  • history of severe hypercapnia or hypoxemia
  • overt congestive heart failure
  • history of severe hypokalemia (<3.0 mmol/l) or hyperkalemia (>6.5 mmol/L) within 3 months prior to study inclusion.

结局指标

主要结局

T50-Laboratory Test for measuring calcification

时间窗: 6 Weeks

The intra-individual difference of T50-times between low (27 mmol/l) and high (37 mmol/l) dialysate bicarbonate prescription.

次要结局

  • CPP Levels(6 Weeks)

研究者

发起方
Prim. Priv. Doz. Dr. Daniel Cejka
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Prim. Priv. Doz. Dr. Daniel Cejka

Principal Investigator

Elisabethinen Hospital

研究点 (2)

Loading locations...

相似试验